198 related articles for article (PubMed ID: 12721240)
21. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
22. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation.
Demers M; Dagnault A; Desjardins J
Clin Nutr; 2014 Oct; 33(5):761-7. PubMed ID: 24200199
[TBL] [Abstract][Full Text] [Related]
23. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
24. Effect of oral sucralfate on late rectal injury associated with radiotherapy for prostate cancer: A double-blind, randomized trial.
Kneebone A; Mameghan H; Bolin T; Berry M; Turner S; Kearsley J; Graham P; Fisher R; Delaney G
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1088-97. PubMed ID: 15519779
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of sucralfate in the prophylaxis of diarrhea secondary to acute radiation-induced enteritis. Preliminary results of a double-blind randomized trial].
Valls A; Algara M; Domènech M; Lladó A; Ferrer E; Marín S
Med Clin (Barc); 1991 Mar; 96(12):449-52. PubMed ID: 2056783
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
27. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
Greven K; Winter K; Underhill K; Fontenesci J; Cooper J; Burke T;
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):168-73. PubMed ID: 15093913
[TBL] [Abstract][Full Text] [Related]
28. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
Hauschild A; Agarwala SS; Trefzer U; Hogg D; Robert C; Hersey P; Eggermont A; Grabbe S; Gonzalez R; Gille J; Peschel C; Schadendorf D; Garbe C; O'Day S; Daud A; White JM; Xia C; Patel K; Kirkwood JM; Keilholz U
J Clin Oncol; 2009 Jun; 27(17):2823-30. PubMed ID: 19349552
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of the therapeutic effect and the safety of glutamine granules per os in patients with severe burns and trauma].
Peng X; You ZY; Huang XK; Zhang CQ; He GZ; Xie WG; Quan ZF; Wang SL
Zhonghua Shao Shang Za Zhi; 2004 Aug; 20(4):206-9. PubMed ID: 15447818
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
[TBL] [Abstract][Full Text] [Related]
31. Clinical trial: normal diet vs. partial replacement with oral E028 formula for the prevention of gastrointestinal toxicity in cancer patients undergoing pelvic radiotherapy.
McGough C; Wedlake L; Baldwin C; Hackett C; Norman AR; Blake P; Harrington K; Tait D; Khoo V; Frost G; Andreyev HJ
Aliment Pharmacol Ther; 2008 Jun; 27(11):1132-9. PubMed ID: 18315590
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
[TBL] [Abstract][Full Text] [Related]
33. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).
Johnson EA; Marks RS; Mandrekar SJ; Hillman SL; Hauge MD; Bauman MD; Wos EJ; Moore DF; Kugler JW; Windschitl HE; Graham DL; Bernath AM; Fitch TR; Soori GS; Jett JR; Adjei AA; Perez EA
Lung Cancer; 2008 May; 60(2):200-7. PubMed ID: 18045731
[TBL] [Abstract][Full Text] [Related]
34. Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial.
Veness MJ; Foroudi F; Gebski V; Timms I; Sathiyaseelan Y; Cakir B; Tiver KW
Australas Radiol; 2006 Oct; 50(5):468-74. PubMed ID: 16981945
[TBL] [Abstract][Full Text] [Related]
35. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
36. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
[TBL] [Abstract][Full Text] [Related]
37. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial.
Wu HG; Song SY; Kim YS; Oh YT; Lee CG; Keum KC; Ahn YC; Lee SW
Cancer; 2009 Aug; 115(16):3699-708. PubMed ID: 19514089
[TBL] [Abstract][Full Text] [Related]
39. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
40. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
